Peter End

2.3k total citations · 1 hit paper
23 papers, 1.9k citations indexed

About

Peter End is a scholar working on Molecular Biology, Hematology and Cell Biology. According to data from OpenAlex, Peter End has authored 23 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Hematology and 5 papers in Cell Biology. Recurrent topics in Peter End's work include Protein Kinase Regulation and GTPase Signaling (5 papers), Pharmacogenetics and Drug Metabolism (4 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Peter End is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (5 papers), Pharmacogenetics and Drug Metabolism (4 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). Peter End collaborates with scholars based in Switzerland, United Kingdom and United States. Peter End's co-authors include George Panayotou, Jürgen ENGEL, Monique Aumailley, Michael D. Waterfield, Rupert Timpl, Gerd A. Kullak‐Ublick, Raúl J. Andrade, Michael Merz, Guruprasad P. Aithal and Alexander L. Gerbes and has published in prestigious journals such as Cell, Journal of Biological Chemistry and Nature Biotechnology.

In The Last Decade

Peter End

22 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Drug-induced liver injury: recent advances in diagnosis and risk assessment

2017 344 citations Gerd A. Kullak‐Ublick, Raúl J. Andrade et al. Gut profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter End Switzerland	16	795	312	275	247	241	23	1.9k
S. Calandra Italy	39	1.5k 1.9×	77 0.2×	410 1.5×	413 1.7×	211 0.9×	187	5.2k
Patrick L. Coleman United States	21	494 0.6×	82 0.3×	143 0.5×	75 0.3×	200 0.8×	41	1.7k
Roberta Baetta Italy	22	621 0.8×	95 0.3×	304 1.1×	61 0.2×	319 1.3×	39	2.1k
Constantino Martı́nez Spain	33	985 1.2×	49 0.2×	132 0.5×	148 0.6×	544 2.3×	101	2.8k
Lise Binderup Denmark	40	1.8k 2.3×	111 0.4×	1.2k 4.5×	492 2.0×	602 2.5×	138	5.1k
Masahiro Tsuda Japan	28	1.1k 1.3×	95 0.3×	1.5k 5.5×	100 0.4×	722 3.0×	127	3.5k
Amy Simon United States	19	1.5k 1.9×	56 0.2×	483 1.8×	94 0.4×	588 2.4×	42	3.1k
Varsha Kaushal United States	20	656 0.8×	46 0.1×	253 0.9×	86 0.3×	87 0.4×	31	1.5k
Chee M. Ng United States	23	503 0.6×	119 0.4×	481 1.7×	26 0.1×	239 1.0×	57	1.7k
Kenji Kumaki United States	18	990 1.2×	230 0.7×	528 1.9×	43 0.2×	218 0.9×	40	1.8k

Countries citing papers authored by Peter End

Since Specialization

Citations

This map shows the geographic impact of Peter End's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter End with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter End more than expected).

Fields of papers citing papers by Peter End

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter End. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter End. The network helps show where Peter End may publish in the future.

Co-authorship network of co-authors of Peter End

This figure shows the co-authorship network connecting the top 25 collaborators of Peter End. A scholar is included among the top collaborators of Peter End based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter End. Peter End is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schiller, Hilmar, Felix Huth, Anton Drollmann, et al.. (2022). Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions. European Journal of Pharmaceutical Sciences. 172. 106155–106155. 4 indexed citations

Jensen, Timothy C., et al.. (2021). A Unidirectional 96-Well Fluidic Culture Platform for Upstream Cell Dosing with Subsequent Downstream Nonlinear and Ascending Exposure Gradients for Real-Time and Cell-Based Toxicity Screening Environments. PubMed. 7(4). 175–191. 1 indexed citations

Risitano, Antonio M., Alexander Röth, Juliette Soret, et al.. (2021). Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. The Lancet Haematology. 8(5). e344–e354. 69 indexed citations

Kaul, Martin, Peter End, Maciej Cabanski, et al.. (2021). Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clinical and Translational Science. 14(5). 1756–1768. 59 indexed citations

Huth, Felix, Hilmar Schiller, Yi Jin, et al.. (2021). Novel Bruton’s Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling. Clinical and Translational Science. 15(1). 118–129. 6 indexed citations

Wong, Edwin, Manuel Praga, Carla Nester, et al.. (2020). LNP023: A Novel Oral Complement Alternative Pathway Factor B Inhibitor Safely and Effectively Reduces Proteinuria in C3 Glomerulopathy. Journal of the American Society of Nephrology. 31(10S). 55–55. 4 indexed citations

Walles, Markus, Alan Brown, Alfred Zimmerlin, & Peter End. (2020). New Perspectives on Drug-Induced Liver Injury Risk Assessment of Acyl Glucuronides. Chemical Research in Toxicology. 33(7). 1551–1560. 23 indexed citations

Webb, Nicholas J.A., Börje Haraldsson, Anna Schubart, et al.. (2020). MO042LNP023: A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR FOR THE TREATMENT OF GLOMERULAR DISEASE. Nephrology Dialysis Transplantation. 35(Supplement_3). 5 indexed citations

Poller, Birk, Ralph Woessner, Avantika Barve, et al.. (2019). Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes. Pulmonary Pharmacology & Therapeutics. 57. 101809–101809. 8 indexed citations

10.

Kullak‐Ublick, Gerd A., Raúl J. Andrade, Michael Merz, et al.. (2017). Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 66(6). 1154–1164. 344 indexed citations breakdown →

11.

Pearson, David, H. Weiss, Yi Jin, et al.. (2017). Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro. Drug Metabolism and Disposition. 45(7). 817–825. 16 indexed citations

12.

Reilly, John, Sarah Williams, Cornelia J. Forster, et al.. (2015). High-Throughput Melanin-Binding Affinity and In Silico Methods to Aid in the Prediction of Drug Exposure in Ocular Tissue. Journal of Pharmaceutical Sciences. 104(12). 3997–4001. 18 indexed citations

13.

Pan, Shifeng, Nathanael S. Gray, Wenqi Gao, et al.. (2013). Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Medicinal Chemistry Letters. 4(3). 333–337. 130 indexed citations

14.

Dieterle, Frank, Elias Perentes, André Cordier, et al.. (2010). Urinary clusterin, cystatin C, β2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nature Biotechnology. 28(5). 463–469. 263 indexed citations

15.

Waldmeier, Felix, Ulrike Glaenzel, B. Wirz, et al.. (2007). Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers. Drug Metabolism and Disposition. 35(8). 1418–1428. 104 indexed citations

16.

Panayotou, George, G Gish, Peter End, et al.. (1993). Interactions Between SH2 Domains and Tyrosine-Phosphorylated Platelet-Derived Growth Factor β-receptor Sequences: Analysis of Kinetic Parameters by a Novel Biosensor-Based Approach. Molecular and Cellular Biology. 13(6). 3567–3576. 31 indexed citations

17.

Panayotou, George, M.D. Waterfield, & Peter End. (1993). Riding the evanescent wave. Current Biology. 3(12). 913–915. 15 indexed citations

18.

End, Peter, George Panayotou, Alan Entwistle, Michael D. Waterfield, & Matthias Chiquet. (1992). Tenascin: a modulator of cell growth. European Journal of Biochemistry. 209(3). 1041–1051. 78 indexed citations

19.

Ellis, Christine, Michael Reedijk, Deborah H. Anderson, et al.. (1992). SH2 Domains of the p85α Subunit of Phosphatidylinositol 3-Kinase Regulate Binding to Growth Factor Receptors. Molecular and Cellular Biology. 12(3). 991–997. 181 indexed citations

20.

Panayotou, George, Peter End, Monique Aumailley, Rupert Timpl, & Jürgen ENGEL. (1989). Domains of laminin with growth-factor activity. Cell. 56(1). 93–101. 280 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact